All In Biotech

Drug Trial Radar · NCT06833749

Efficacy and Safety of KBP-336 in Obese Individuals with Osteoarthritis

A Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of KBP-336 As an Adjunct to Diet and Exercise in Obese Individuals with Osteoarthritis of the Knee

Last checked: Nov 19, 2026Latest source record: Feb 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

600

Planned (sponsor's estimate)

Start

Jan 28, 2025

Primary completion

Nov 2026

Study completion Dec 2026

Sponsor

Lead sponsor
KeyBioscience AGIndustry
Sponsor type
Industry
First posted
Feb 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if KBP-336 works to treat pain in osteoarthritis in individuals living with obesity. It will also learn about the effects on other parameters, such as quality of life and metabolism, as well as safety of KBP-336. The main questions it aims to answer are: * Does KBP-336 lower knee pain from osteoarthritis in individuals with obesity * Does KBP-336 lower bodyweight in the same population. Researchers will compare KBP-336 to a placebo (a look-alike substance that contains no drug) to see if KBP-336 works to pain and obesity Participants will: * Take KBP-336 or a placebo every week for 6 months * Visit the clinic once every 2 weeks for checkups and tests * Keep a diary of their symptoms and the amount of medication they use in addition to KBP-336

Conditions

  • Osteoarthritis in the Knee
  • Obesity

Interventions

  • KBP-336Drug

    KBP-336 is a long acting Dual Amylin and Calcitonin Receptor agonist designed for weekly administration through subcutaneous injection.

  • PlaceboDrug

    Placebo to match KBP-336

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportional change in body weight from baseline to endpointTime frame: 183 Days
  2. The change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain scale from baseline to endpointTime frame: 183 Days

Locations

20 sites in 6 countries. Site status is shown where the registry gives one.

  • Pratia Brno, s.r.o

    Brno, Czechia · Not yet recruiting

  • L.K.N. Artrocentrum

    Hlučín, Czechia · Not yet recruiting

  • Medical Plus, s.r.o

    Hradiště, Czechia · Not yet recruiting

  • Pratia Pardubice a.s.

    Pardubice, Czechia · Not yet recruiting

  • Affidea Praha s.r.o

    Prague, Czechia · Not yet recruiting

  • Pratia Prague, s.r.o

    Prague, Czechia · Not yet recruiting

  • Sanos Clinic Nordjylland

    Gandrup, Denmark · Recruiting

  • Sanos Clinic Herlev

    Herlev, Denmark · Recruiting

  • Sanos Clinic Syddanmark

    Vejle, Denmark · Recruiting

  • Hong Kong Center for Clinical Research

    Hong Kong, Hong Kong · Not yet recruiting

  • IMSP Sptalul Clinic Municipal "Sfanta Treime"

    Chisinau, Moldova · Not yet recruiting

  • PMSI Cardiology Institute/RTL SM SRL

    Chisinau, Moldova · Not yet recruiting

  • Timofei Mosneaga Republican Clinical Hospital

    Chisinau, Moldova · Not yet recruiting

  • NZOZ Bif-Med. s.c.

    Bytom, Poland · Not yet recruiting

  • Medyczne Centrum Hetmańska

    Poznan, Poland · Not yet recruiting

  • DC-MED SP z o.o.

    Swidnica, Poland · Not yet recruiting

  • NZOZ Lecznica MAK-MED s.c.

    Warsaw, Poland · Not yet recruiting

  • Migre Polskie Centrum Leczenia Migreny

    Wroclaw, Poland · Not yet recruiting

  • Policlinica CCBR

    Bucharest, Romania · Not yet recruiting

  • Quantum Medical Bucharest

    Bucharest, Romania · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.